natgillin/translations-raw huggingface dataset:
Detailed information on this product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/
Podrobne informacije o produktu so na voljo na spletni strani Evropske agencije za zdravila (EMEA) http: / www. emea. europa. eu
Dicural Coated Tablets consist of a core tablet containing difloxacin hydrochloride and a highly palatable coating.
Pokrite so s filmsko oblogo.
Difloxacin is an aryl-fluoroquinolone with a broad spectrum of antimicrobial activity.
Difloksacin je fluoriran aril- kinolonski derivat s širokim spektrom protimikrobnega učinkovanja.
Streptococcus canis (beta) Streptococcus spp.
49/ 63 Streptococcus canis (beta) Streptococcus spp.
The elimination half-life averaged 9.3 hours.
Razpolovni čas izločanja znaša približno 9, 3 ur.
50/ 64 Long term daily oral treatment over 180 days at 5 mg/ kg bodyweight did not influence difloxacin kinetics, neither by accumulation nor by increased drug metabolism.
Tudi dolgotrajno dajanje zdravila (čez 180 dni) v odmerku 5 mg/ kg telesne mase ni imelo vpliva na kinetiko difloksacina – ne na njegovo akumulacijo in ne na povečanje njegovega metabolizma.
Dicural 50 mg/ ml solution for injection for cattle and dogs
52/ 63 NAVODILO ZA UPORABO Dicural 50 mg/ ml, raztopina za injiciranje za goveda in pse
Dicural 50 mg/ ml solution for injection for cattle and dogs
Dicural 50 mg/ ml, raztopina za injiciranje za goveda in pse
Cattle:
Govedo Zdravljenje respiratornih obolenj (transportna mrzlica, pljučnice pri teletih), ki jih povzročajo - samostojno ali v kombinaciji naslednji mikroorganizmi:
Dogs: treatment of: • Acute uncomplicated urinary tract infections caused by Escherichia coli or Staphylococcus spp • Superficial pyoderma caused by Staphylococcus intermedius.
Zdravljenje površinske pioderme, ki jo povzroča Staphylococcus intermedius.
None.
Govedo Niso znane.
As for other quinolones, due to possible adverse effects on the articular cartilage of weight bearing joints difloxacin should not be used during the rapid growth phase, that is,. do not use in small and medium-sized breeds of dogs up to and including 8 months of age, in large breeds up to 1 year of age and in giant breeds up to 18 months of age.
Psi Tako kot drugi fluorokinoloni tudi difloksacin učinkuje zaviralno na rast in obnavljanje sklepnega hrustanca, zato ga ne uporabite pri psih v fazi hitre rasti, ki je pri majhnih in srednje velikih pasmah
The recommended dose is 2.5 mg difloxacin/ kg bodyweight per day for 3 days (that is, 5ml/ 100 kg bodyweight) by subcutaneous administration.
Priporočljiv dnevni odmerek difloksacina je 2, 5 mg/ kg telesne mase v obdobju 3 dni (to ustreza 5 ml/ kg telesne/ dan).
For complicated respiratory disease the dose can be doubled to 5 mg/ kg bodyweight per day.
Pri hudih respiratornih obolenjih odmerek povečajte na 5 mg/ kg telesne mase/ dan.
The recommended dose is a single subcutaneous injection of 5.0 mg difloxacin/ kg body weight.
Priporočljiv dnevni odmerek difloksacina znaša 5, 0 mg/ kg telesne mase in se aplicira subkutano.
Treatment must then be continued with Dicural Coated Tablets (read the Package Leaflet for that product).
Zdravljenje morate nadaljevati z Dicural filmsko obloženimi tabletami (preberite navodilo za uporabo tega zdravila).
In cattle, the volume administered per injection site should not exceed 7 ml.
Govedo Na eno mesto aplicirajte največ 7 ml.
In dogs, the volume administered per injection site should not exceed 5 ml.
Psi Na eno mesto aplicirajte največ 5 ml.
Cattle:
Govedo: Meso in organi:
Meat and offal 46 days
46 dni
Do not freeze.
54/ 63 Zdravilo ne sme zmrzniti.
28 days.
Rok uporabnosti zdravila po prvem odprtju vsebnika: 28 dni.
Do not use after the expiry date stated on the vial.
Zdravila ne smete uporabljati po datumu izteka uporabnosti, navedenega na ovojnini.
Dicural 50 mg/ ml solution for injection should only be used based on susceptibility testing.
Zdravilo uporabite v skladu z lokalnimi priporočili s področja protimikrobnega zdravljenja.
The safety of the veterinary medicinal product has not been established during pregnancy and lactation.
Če je le mogoče, se zdravljenje s fluorokinoloni izvaja po predhodnem testiranju občutljivosti povzročiteljev.
Overdose
Preveliki odmerki:
In another study dogs treated orally with difloxacin at 10 times the recommended dose for 10 days showed occasionally mild adverse reactions such as orange/ yellowing discoloration of the faeces, emesis and hypersalivation.
Pri desetkrat večjih odmerkih, danih peroralno v obdobju 10 dni, pa so se pokazali blagi neželeni učinki, kot je rumeno- oranžno obarvano blato, emezija in povečano slinjenje
Detailed information on this product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu
Podrobne informacije o produktu so na voljo na spletni strani Evropske agencije za zdravila (EMEA) http: / www. emea. europa. eu
15.
55/ 63 15.
Dicural 50 mg/ ml, solution for injection for cattle and dogs is available in the following presentations:
Dicural 50 mg/ ml, raztopina za injiciranje za govedo in pse je na razpolago v naslednjih pakiranjih:
Dogs:
Za pse:
Cattle:
50 ml viala Za goveda:
50, 100 and 250 ml vials.
100 in 250 ml viala
59/ 64 PACKAGE LEAFLET Dicural 50 mg/ ml, solution for injection for cattle
58/ 63 NAVODILO ZA UPORABO Dicural 50 mg/ ml, raztopina za injiciranje za goveda
Manufacturer for the batch release Fort Dodge Veterinaria S. A.
Izdelovalec, odgovoren za sproščanje serije Fort Dodge Veterinaria S. A.
Carretera Camprodón, s/ n - La Riba 17813-Vall de Bianya (Girona) Spain
Ctra. Camprodon s/ n La Riba, 17813 Vall de Bianya (Gerona) Spain
Dicural 50 mg/ ml, solution for injection for cattle
Dicural 50 mg/ ml, raztopina za injiciranje za goveda
Active substance Difloxacin (as the hydrochloride)
Zdravilne učinkovine Difloksacin (v obliki klorida)
In target animal safety studies, subcutaneous administration in cattle was generally well tolerated.
Ciljne živali zdravilo na splošno dobro prenašajo.
The dose by subcutaneous administration for cattle is 2.5 mg difloxacin/ kg bodyweight per day for 3 days (that is, 5ml/ 100 kg bodyweight).
Priporočljiv dnevni odmerek difloksacina znaša 2, 5 mg/ kg telesne mase v obdobju 3 dni (to ustreza 5 ml/ kg telesne mase/ dan).
If there is no sufficient improvement after 3 days, the treatment can be continued for another 2 days.
Če po treh dneh zdravljenja ni bistvenega izboljšanja, nadaljujte z zdravljenjem še dva dni.
For complicated respiratory disease the dose can be doubled to 5 mg/ kg per day.
Pri hudih respiratornih obolenjih odmerek povečajte na 5 mg/ kg telesne mase/ dan.
Subcutaneous use.
Dnevno dajte zdravilo na drugo mesto.
In cattle, the volume administered per injection site should not exceed 7 ml; consecutive daily doses have to be administered at different injection sites.
Dnevno dajte zdravilo na drugo mesto.
Shelf-life after first use of the product:
Rok uporabnosti zdravila po prvem odpiranju vsebnika:
Do not use after the expiry date stated on the vial.
Zdravila ne smete uporabljati po datumu izteka uporabnosti, navedenega na nalepki.
The use of fluoroquinolones in combination with non-steroidal anti-inflammatory drugs (NSAIDs) may cause seizures.
Pri uporabi zdravila brez upoštevanja podatkov, ki so navedeni v povzetku glavnih značilnosti zdravila (SPC) lahko pride do zmanjšanja prevalence bakterijske rezistence na fluorokinolone in zmanjšanja učinkovitosti zdravljenja z drugimi kinoloni zaradi možne navskrižne rezistence.
Antagonism may be observed with nitrofurantoin.
Ni dokazana varnost zdravila v obdobju brejosti in laktacije.
People with a known hypersensitivity to quinolones should avoid any contact with the product.
Kombinacija fluorokinolonov in nestereoidnih antiinflamatorikov (NSAID) lahko pri epilepsiji izzove napad.
61/ 64 Overdose At very high doses adverse effects on the nervous system (ataxia, unsteadiness, twitching, tremors, convulsions, etc.) may occur in cattle; in this target species overdosing may also give rise to oedema and swelling in the knee joints.
60/ 63 Fluorokinoloni in nitrofurani učinkujejo medsebojno antagonistično.
No specific antidote for difloxacin (or other quinolones) is known.
Osebe z znano preobčutljivostjo na kinolone naj se izogibajo stiku z zdravilom.
Therefore in case of overdosage symptomatic treatment should be given
Pri zelo velikih odmerkih se pokažejo učinki na živčni sistem (ataksija, zanašanje, drgetanje, krči in drugo).
To be supplied only on veterinary prescription.
Uporablja se le na osnovi recepta veterinarja.
Dicural 50 mg/ ml, solution for injection for cattle is available in 50, 100 and 250 ml vials.
Dicural 50 mg/ ml raztopina za injiciranje za goveda je na razpolago v 50, 100 in 250 ml vialah.
EMEA/ C/ V/ 077
EMEA/ V/ C/ 077
If you need more information about your animal’ s medical condition or treatment, contact your veterinarian.
Če potrebujete več informacij o uporabi tega izdelka, se posvetujte z vašim nacionalnim veterinarskim organom.
What is DRAXXIN?
Kaj je zdravilo DRAXXIN?
DRAXXIN contains tulathromycin, which belongs to a class of medicines having an antibiotic action.
DRAXXIN vsebuje tulatromicin, ki spada v skupino zdravil z antibiotičnim delovanjem.
DRAXXIN is a solution for injection (100 mg/ ml).
DRAXXIN je raztopina za injiciranje (100 mg/ ml).
What is DRAXXIN used for?
Za kaj se zdravilo DRAXXIN uporablja?
DRAXXIN can also be used to prevent BRD and SRD. The medicine should only be used for prevention in cattle and pigs once the presence of the disease in the herd has been established, and for pigs if they are expected to develop the disease within two to three days.
Zdravilo DRAXXIN se uporablja za zdravljenje naslednjih bolezni, če jih povzročajo bakterije, ki so občutljive na tulatromicin:
DRAXXIN is given as a single injection of 2.5 mg per kilogram body weight.
dihalnih obolenj goveda (BRD), ki ga povzročajo Mannheimia haemolytica, Pasteurella multocida, Histophilus somni ali Mycoplasma bovis,
In cattle, it is injected under the skin, and the dose is divided in cattle weighing over 300 kg so that no more than 7.5 ml are injected at one site.
infekcioznega govejega keratokonjuktivitisa (IBK) pri govedu, obolenja oči, ki ga povzroča Moraxella bovis,
In pigs it is injected into a muscle, and the dose is divided in pigs weighing over 80 kg so that no more than 2 ml are injected at one site.
dihalnih obolenj prašičev (SRD), ki ga povzročajo Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae ali Haemophilus parasuis.
It is recommended that animals are treated in the early stages of the disease and that their response is evaluated within 48 hours.
Zdravilo DRAXXIN se lahko uporablja tudi za preprečevanje dihalnih obolenj goveda in dihalnih obolenj prašičev.
If symptoms continue to be present, get worse or come back, treatment should be changed to another antibiotic.
Zdravilo se lahko za preprečevanje obolenja pri govedu in prašičih uporablja šele potem, ko je bila v čredi ugotovljena prisotnost bolezni, pri prašičih pa, če se pričakuje, da se bo pri njih v dveh do treh dneh razvila bolezen.
The active substance in DRAXXIN, tulathromycin, is an antibiotic that belongs to the class ‘ macrolides’.
Zdravilo DRAXXIN se daje kot enkratna injekcija v odmerku 2, 5 mg na kilogram telesne mase.
It works by attaching to the RNA (the molecules that instruct the cell how to make proteins) within the bacterial cells.
Pri govedu se injicira pod kožo, pri govedu s telesno težo več kot 300 kg pa se odmerek razdeli tako, da se na enem mestu ne injicira več kot 7, 5 ml.
This prevents the bacteria being able to make vital proteins and stops them growing and multiplying.
Pri prašičih se injicira v mišico, pri prašičih s telesno težo več kot 80 kg pa se odmerek razdeli tako, da se na enem mestu ne injicirata več kot 2 ml zdravila.
DRAXXIN is effective against the bacteria that most commonly cause BRD, SRD and IBK.
Priporočljivo je, da se živali zdravi v zgodnjih fazah bolezni, njihov odziv na zdravljenje pa se oceni v 48 urah.
However, some bacteria can develop resistance against tulathromycin, which will reduce its effectiveness.
Če so simptomi še vedno prisotni, se poslabšujejo ali pa se ponovno pojavijo, je treba preiti na zdravljenje z drugim antibiotikom.
(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail@emea. europa. eu http: / /www. emea. europa. eu © EMEA European Medicines Agency, 2008.
(44- 20) 74 18 84 00 Fax (44- 20) 74 18 84 46 E- mail: mail@ emea. europa. eu http: // www. emea. europa. eu © EMEA European Medicines Agency, 2008.
Reproduction is authorised provided the source is acknowledged How has DRAXXIN been studied?
Reproduction is authorised provided the source is acknowledged Kako zdravilo DRAXXIN deluje?
The effectiveness of DRAXXIN in treating or preventing BRD has been studied in nine main studies involving calves, carried out during an outbreak of the disease.
Deluje s pripojitvijo na RNA (molekule, ki celici dajejo navodila, kako tvoriti beljakovine) v celicah bakterij.
In the treatment studies, the cattle were infected with BRD-causing bacteria, but the cattle in the prevention studies had no symptoms of the disease.
Vendar pa se pri nekaterih bakterijah lahko razvije odpornost na tulatromicin, kar zmanjša njegovo učinkovitost.
DRAXXIN was compared with tilmicosin or florfenicol (other antibiotics), and, in the prevention studies also with placebo (a dummy treatment).
Zdravilo DRAXXIN so primerjali z zdravilom tilmikozin ali zdravilom florfenikol (drugima antibiotikoma), v študijah preprečevanja bolezni pa tudi s placebom (zdravilom brez zdravilne učinkovine).
The main measure of effectiveness was the change in symptoms, including body temperature, breathing and recovery over a period of between two weeks and two months.
Najpomembnejše merilo učinkovitosti je bila sprememba simptomov, vključno s telesno temperaturo, dihanjem in okrevanjem v obdobju od dveh tednov do dveh mesecev.
For the treatment of IBK, the effectiveness of DRAXXIN has been studied in three main studies involving calves.
Pri zdravljenju infekcioznega govejega keratokonjuktivitisa so učinkovitost zdravila DRAXXIN raziskovali v treh glavnih študijah, v katere so bila vključena teleta.
In two studies, it was compared with the effectiveness of placebo, but the third also compared it to oxytetracycline (another antibiotic).
V dveh študijah so ga primerjali z učinkovitostjo placeba, v tretji pa so ga primerjali tudi z oksitetraciklinom (drugim antibiotikom).
The main measure of effectiveness was the proportion of cattle whose disease had been cured after three weeks.
Najpomembnejše merilo učinkovitosti je bil delež telet, pri katerih je do ozdravitve bolezni prišlo po treh tednih.
The effectiveness of DRAXXIN in treating SRD has been studied in pigs in two main studies, where it was compared with tiamulin or florfenicol.
Učinkovitost zdravila DRAXXIN pri zdravljenju dihalnih obolenj prašičev so raziskovali pri prašičih v dveh glavnih študijah, v katerih so ga primerjali z zdravilom tilmikozin ali zdravilom florfenikol.
The main measure of effectiveness was the change in symptoms over 10 days.
Najpomembnejše merilo učinkovitosti je bila sprememba simptomov v 10 dneh.
For the prevention of SRD, the effectiveness of DRAXXIN was studied in six main studies, in which it was compared with placebo.
Pri preprečevanju dihalnih obolenj prašičev so učinkovitost zdravila DRAXXIN raziskovali v šestih glavnih študijah, v katerih so ga primerjali s placebom.
The main measure of effectiveness was the proportion of pigs that completed the full three or six weeks of each study without needing to be removed from the study because of SRD.
Najpomembnejše merilo učinkovitosti je bil delež prašičev, ki so zaključili celotno obdobje treh ali šestih tednov trajanja vsake študije, ne da bi jih bilo treba izločiti iz študije zaradi dihalnih obolenj prašičev.
What benefit has DRAXXIN shown during the studies?
Kakšne koristi je zdravilo DRAXXIN izkazalo v raziskavah?
A single 2.5-mg/ kg dose of DRAXXIN was effective in treating and preventing BRD in cattle and SRD in pigs.
Enkratni odmerek v višini 2, 5 mg/ kg zdravila DRAXXIN je bil učinkovit pri zdravljenju in preprečevanju dihalnih obolenj goveda in dihalnih obolenj prašičev.
In all studies, DRAXXIN was at least as effective as the comparator medicines.
V vseh študijah je bilo zdravilo DRAXXIN vsaj tako učinkovito kot primerjalna zdravila.
Looking at the studies taken together, it was more effective than placebo.
Ob presojanju vseh študij skupaj je bilo učinkovitejše kot placebo.
In two of the three studies of IBK, DRAXXIN was more effective than placebo in curing the disease.
V dveh izmed treh študij infekcioznega govejega keratokonjuktivitisa je bilo zdravilo DRAXXIN učinkovitejše kot placebo pri ozdravljenju bolezni.
However, the third study found no difference between the effectiveness of DRAXXIN, oxytetracycline and placebo.
Vendar pa v tretji študiji niso ugotovili nobene razlike med učinkovitostjo zdravila DRAXXIN, oksitetraciklina in placeba.
What is the risk associated with DRAXXIN?
Kakšna tveganja so povezana z dajanjem zdravila DRAXXIN?
The subcutaneous injection of DRAXXIN to cattle often causes temporary pain and swelling at the injection site, which can last up to 30 days.
Podkožno injiciranje zdravila DRAXXIN govedu pogosto povzroča začasno bolečino in oteklino na mestu injiciranja, ki lahko traja do 30 dni.
These reactions have not been seen in pigs after intramuscular injection.
Teh reakcij pri prašičih po intramuskularnem injiciranju niso opazili.
Other types of reaction to the injection persist for about 30 days after injection in cattle and pigs.
Druge vrste reakcij na injekcijo so pri govedu in prašičih prisotne v obdobju približno 30 dni po injiciranju.
DRAXXIN should not be used in animals that are hypersensitive (allergic) to macrolideantibiotics.
Zdravila DRAXXIN se ne sme uporabljati pri živalih, ki so preobčutljive za (alergične na) makrolidne antibiotike.
It should also not be used at the same time as other macrolide antibiotics or lincosamides (another type of antibiotic medicine), in cattle that are producing milk for human consumption, or in pregnant cows intended to produce milk for human consumption within two months of their expected date of giving birth.
Prav tako se ga ne sme uporabljati ob istem času kot druge makrolidne antibiotike ali linkozamide (druge vrste antibiotičnega zdravila) pri govedu, ki daje mleko za prehrano ljudi, ali pri brejih kravah, namenjenih pridobivanju mleka za prehrano ljudi, v obdobju dveh mesecev pred pričakovanim datumom telitve.
What are the precautions for the person who gives the medicine or comes into contact with the animal?
stran 2/ 3 ©EMEA 2008 Kakšne previdnostne ukrepe mora upoštevati oseba, ki daje zdravilo ali pride v stik z živaljo?
DRAXXIN can irritate the eyes.
Zdravilo DRAXXIN lahko draži oči.
If DRAXXIN accidentally get into the eyes, flush them immediately with clean water.
Če zdravilo DRAXXIN po naključju zaide v oči, jih je treba takoj sprati s čisto vodo.
DRAXXIN may also cause sensitisation (redness, itching and swelling) if it comes into contact with the skin.
Zdravilo DRAXXIN lahko povzroči tudi senzibilizacijo (rdečico, srbenje in oteklino), če pride v stik s kožo.
If accidental skin exposure occurs, wash the skin immediately with soap and water.
V primeru nenamernega stika s kožo, kožo takoj sperite z milom in vodo.
In case of accidental self- injection, seek medical advice immediately and show the Package Leaflet or the label to the doctor.
V primeru nenamernega samoinjiciranja se takoj posvetujte z zdravnikom in mu pokažite navodilo za uporabo ali nalepko na zunanji ovojnini.
What is the time to allow before the animal can be slaughtered and the meat used for human consumption?
Koliko časa je potrebno počakati, preden se žival lahko zakolje in meso uporabi za prehrano ljudi?
For cattle intended for consumption as either meat or offal, 49 days must be allowed before slaughter.
Pri govedu, namenjenem za uporabo bodisi mesa ali drobovine, mora preteči 49 dni, preden se žival lahko zakolje.
For pigs intended for consumption as either meat or offal, 33 days must be allowed.
Pri prašičih, namenjenih za uporabo bodisi mesa ali drobovine, mora preteči 33 dni.
What is the time to allow before milk can be taken from the animal for human consumption?
Koliko časa mora preteči preden se lahko od živali pridobiva mleko za prehrano ljudi?
DRAXXIN must not be used in cattle that are producing milk for human consumption, or in pregnant cows intended to produce milk for human consumption within two months of their expected date of giving birth.
Zdravila DRAXXIN se ne sme uporabljati pri govedu, ki daje mleko za prehrano ljudi, niti pri brejih kravah, namenjenih pridobivanju mleka za prehrano ljudi, v obdobju dveh mesecev pred pričakovanim datumom telitve.
Why has DRAXXIN been approved?
Zakaj je bilo zdravilo DRAXXIN odobreno?
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of DRAXXIN exceed the risks for the treatment and prevention of BRD and the treatment of IBK in cattle, and for the treatment and prevention of SRD in pigs, and recommended that DRAXXIN be given a marketing authorisation.
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je zaključil, da so koristi zdravila DRAXXIN pri zdravljenju in preprečevanju dihalnih obolenj goveda in zdravljenju infekcioznega govejega keratokonjuktivitisa pri govedu in pri zdravljenju in preprečevanju dihalnih obolenj prašičev, večje od z njim povezanih tveganj, zato je priporočil odobritev dovoljenja za promet z zdravilom DRAXXIN.
The benefit-risk balance may be found in module 6 of this EPAR.
Ocena razmerja med koristmi in tveganji je na voljo v modulu 6 tega evropskega javnega poročila o oceni zdravila (EPAR).
Other information about DRAXXIN:
Druge informacije o zdravilu DRAXXIN:
The European Commission granted a marketing authorisation valid throughout the European Union for DRAXXIN to Pfizer Limited on 23 July 2003.
Evropska komisija je dovoljenje za promet z zdravilom DRAXXIN, veljavno po vsej Evropski uniji, odobrila družbi Pfizer Limited dne 23. julija 2003.
This summary was last updated on 3 October 2007.
Ta povzetek je bil nazadnje posodobljen 3. oktobra 2007.
©EMEA 2008
stran 3/ 3 ©EMEA 2008
Subcutaneous use (cattle) intramuscular use (pigs)
Subkutano (govedo), intramuskularno
Cardboard box with one vial
Kartonasta škatla z eno vialo
49 days Pigs:
49 dni, Prašiči:
49 days Pigs:
49 dni Prašiči:
Subcutaneous use (cattle)
Subkutano (govedo)
Subcutaneous use Cattle (cattle)
Subkutano (govedo)
1 Not for use in lactating cattle producing milk for human consumption.
¹Zdravila ne dajemo govedu v obdobju laktacije, katerih mleko je namenjeno prehrani ljudi.
Not for use in pregnant cows or heifers, which are intended to produce milk for human consumption, within 2 months of expected parturition.
Zdravila ne dajemo brejim kravam ali telicam, katerih mleko je namenjeno prehrani ljudi, v obdobju 2 mesecev pred pričakovanim porodom..
DRAXXIN 100 mg/ ml solution for injection for cattle and pigs
DRAXXIN 100 mg/ ml raztopina za injiciranje za govedo in prašiče
Active substance(s):
Zdravilna učinkovina:
Tulathromycin 100 mg/ ml
Tulatromicin 100 mg/ ml
Cattle Treatment and prevention of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis sensitive to tulathromycin.
Govedo Zdravljenje in preprečevanje dihalnih obolenj goveda (BRD), povzročenih z Mannheimia haemolytica, Pasteurella multocida, Histophilus somni in Mycoplasma bovis občutljivih na tulatromicin.
The presence of the disease in the herd should be established before preventative treatment.
Pred preventivno uporabo je potrebno dokazati prisotnost bolezni v čredi.
Pigs Treatment and prevention of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae, and Haemophilus parasuis sensitive to tulathromycin.
Prašiči Zdravljenje in preprečevanje dihalnih obolenj prašičev (SRD), povzročenih z Actinobacillus pleuropneumoniae, Pastuerella multocida, Mycoplasma hyopneumoniae in Haemophilus parasuis, občutljivih na tulatromicin.